Unitaid

25/09/2025

“By bringing the cost of long-acting injectable HIV prevention on par with oral PrEP, countries now have a stronger economic case to scale up access widely,” said Vincent Bretin, Director of Results and Climate and Health at Unitaid. “This is more than a pricing agreement: it is a breakthrough for prevention, equity, and resilience.”

Through a new agreement with Dr. Reddy’s Laboratories, the Clinton Health Access Initiative, Wits RHI and Unitaid have secured a $40 annual price for injectable lenacapavir, making it accessible in 120 low- and middle-income countries starting in 2027.

This landmark step ensures that a revolutionary HIV prevention tool can reach more people who need protection and demonstrates what is possible when innovation is paired with equity.

Learn more: https://unitaid.org/lenacapavir

25/09/2025

Our heartfelt thanks to all who joined last night’s flagship UNGA event on advancing women’s health. From survivor voices to national leadership and financing partners, your contributions reaffirmed that with innovation, commitment and collaboration, we can close the gaps and save lives.

25/09/2025

At our event last night, survivor and advocate Karen Nakawala shared her story of living through cervical cancer and founding the Teal Sisters Foundation. Her testimony underscored the barriers of stigma, cost, and access, and why lifesaving tools must reach every woman, in every community.

25/09/2025

Last night at our flagship UNGA event, Rwanda shared its bold vision to eliminate cervical cancer by 2027, three years ahead of the global target. With strong political will, nationwide vaccination and screening, and partnerships with Unitaid and others, Rwanda is showing that elimination is possible.

25/09/2025

Last night, we convened leaders and partners to spotlight women’s health as a political and financing priority. Cervical cancer is preventable and treatable. Innovative financing and strong partnerships can turn elimination into a reality for women and girls everywhere.

25/09/2025

“When communities, civil society, and governments work together, access becomes real,” said Tenu Avafia, Deputy Executive Director of Unitaid. “With price parity now secured, we must ensure strong political commitment, sufficient funding, and continued community leadership. If we succeed, this medicine could change the course of the AIDS epidemic and bring us closer to ending HIV as a public health threat.”

Unitaid is working closely with grassroots groups in South Africa, Brazil, and beyond to ensure lenacapavir fits into people’s lives. Communities are not just beneficiaries: they are partners at the heart of this effort. At the same time, Unitaid is supporting governments to plan, budget, and integrate this tool into national HIV programs.

This agreement is a breakthrough for affordable access, but real impact will come from the leadership of communities and civil society working alongside governments to make prevention a reality for all.

Learn more: https://unitaid.org/lenacapavir

24/09/2025

For decades, we have seen a familiar pattern: breakthrough health innovations debut in high-income countries, while low- and middle-income countries wait 10 to 15 years before affordable versions become available. This long delay costs lives and undermines global health equity.

Today, we are demonstrating that it does not have to be this way.

Unitaid, the Clinton Health Access Initiative, Wits RHI and Dr. Reddy's Laboratories Ltd. have secured a US$40 yearly price for lenacapavir, a twice-yearly HIV prevention injection. Starting in 2027, people in 120 low- and middle-income countries will have access to the most advanced prevention tool at the same cost as oral PrEP.

This is a record achievement: affordable generics are expected in under two years following the first regulatory approvals, instead of the usual decade. That speed represents a new benchmark for what is possible with the right partnerships.

Price parity is equally important. By securing a cost of the injectable equal to oral PrEP, we have eliminated a barrier to adoption, making it easier for countries to scale up prevention and for communities to embrace new options.

This deal is more than a price cut, it proves that affordability and speed can be achieved together, redefining access and setting the stage for future innovations to follow the same path.

Find out more: https://unitaid.org/lenacapavir

24/09/2025

“Even the most promising innovation cannot reach its potential without being affordable,” said Carmen Pérez Casas, Senior strategy lead at Unitaid. “Lenacapavir is a revolutionary tool for HIV prevention, but equitable access is what will unlock its full impact.”

That is why Unitaid, the Clinton Health Access Initiative, Wits RHI and Dr. Reddy's Laboratories Ltd. have secured a US$40 annual price for injectable lenacapavir, the same as oral PrEP. Generics are expected in low- and middle-income countries as early as 2027, less than two years after the first regulatory approvals in high-income countries, showing what is possible when affordability is prioritized from the start.

A second US$40 pricing agreement between the Gates Foundation and Hetero was announced today for injectable lenacapavir, helping to grow the market and secure sustainable and sufficient supplies of the breakthrough prevention tool.

Today’s pricing agreements mark a significant step forward in making lenacapavir accessible to millions in need in record time. But our work does not end here. Current licensing agreements do not extend to all countries in need. Finding solutions to expand access in these countries will be critical to ensure no one is left behind.

Our work now is to support countries and communities to drive adoption, remove barriers, and build sustainable markets so lenacapavir can truly reach all who need it and deliver on its promise to transform HIV prevention.

Learn more: https://unitaid.org/lenacapavir

24/09/2025

For 20 years, Unitaid and the Clinton Health Access Initiative have worked together to make lifesaving medicines accessible. Today, that mission delivers again: a twice-yearly HIV prevention injection at just $40 a year for low- and middle-income countries. Equity in action.

Learn more: www.unitaid.org/lenacapavir

24/09/2025

At today, President Bill Clinton announced a landmark price agreement for lenacapavir: a twice-yearly HIV prevention injection will be available in low- and middle-income countries for US$40 per year.

Learn more: https://www.unitaid.org/lenacapavir

24/09/2025

L’innovation change le monde seulement lorsqu’elle est accessible. Trop souvent, les outils vitaux mettent plus d’une décennie à atteindre les pays à revenu faible et intermédiaire à des prix abordables. Pour les médicaments contre le VIH, ce re**rd s’est traduit par des millions de vies qui auraient pu être sauvées.

C’est pourquoi l’annonce d’aujourd’hui marque une étape aussi importante.

Unitaid, la Clinton Health Access Initiative (CHAI), le Wits RHI et Dr. Reddy's Laboratories Ltd. ont conclu un accord historique qui permettra de rendre disponible le lénacapavir injectable – un outil révolutionnaire de prévention du VIH – au prix de seulement 40 USD par personne et par an dans 120 pays à revenu faible et intermédiaire.

Le lénacapavir est une injection semestrielle qui offre la même protection que la PrEP orale quotidienne. Pour beaucoup, il est difficile de prendre un comprimé chaque jour sur le long terme. Le lénacapavir a le potentiel de transformer la prévention en offrant une protection durable avec seulement deux doses par an.

Ce qui rend cette avancée véritablement historique, c’est la rapidité. Des génériques abordables devraient être disponibles dès 2027, soit moins de deux ans après les premières autorisations réglementaires dans les pays à revenu élevé. Dans le domaine de la santé mondiale, c’est un délai record.

Un accord distinct entre la Gates Foundation et Hetero, annoncé également aujourd’hui, viendra élargir encore le marché des génériques pour le lénacapavir injectable, contribuant ainsi à créer une voie d’accès durable et fiable.

Les accords de tarification annoncés aujourd’hui constituent un pas de géant pour rendre le lénacapavir accessible à des millions de personnes dans le besoin. Et cela, en un temps record. Avec l’accessibilité financière, un accès accéléré et le développement du marché, ces accords établissent une nouvelle référence en matière d’équité. Ils démontrent qu’avec les bonnes interventions, les innovations majeures n’ont pas à rester hors de portée de celles et ceux qui en ont le plus besoin.

Mais notre travail ne s’arrête pas là. Les fabricants de génériques restent liés à leurs licences bilatérales avec Gilead Sciences, qui excluent actuellement vingt-six pays à revenu faible et intermédiaire, où surviennent près de 10 % de toutes les nouvelles infections au VIH. Les questions essentielles concernant l’accès à des génériques à bas prix dans ces pays doivent être traitées de toute urgence. Si nous célébrons aujourd’hui une étape importante, nous restons résolument engagés à soutenir une voie d’accès dans l’ensemble des pays à revenu faible et intermédiaire.

En savoir plus : www.unitaid.org/lenacapavir-fr

cc. Représentation permanente de la France auprès de l’ONU à Genève, Results Canada

Unitaid, CHAI et Wits RHI concluent un accord historique avec Dr. Reddy’s pour rendre l’outil de prévention du VIH, le lénacapavir, abordable dans les pays à revenu faible et intermédiaire

24/09/2025

Together with Unitaid, Wits RHI, and Dr. Reddy's Laboratories Ltd., we are announcing a historic breakthrough in HIV prevention today:

A twice-yearly injection that's nearly 100% effective at preventing HIV will now cost just US$40 for an entire year across 120 low- and middle-income countries.

This isn't just a medical breakthrough - it's hope becoming reality for millions.

As Unitaid's Executive Director Dr. Philippe Duneton said: "Securing a US$40 price for the twice-yearly lenacapavir injection for PrEP is a historic breakthrough that proves the most advanced tools can be made affordable from the very start."

Later today, President Clinton will join Health Ministers from across Africa to announce this historic partnership.

120 countries. US$40 per year. Available by 2027.

When global health gets it right, it changes everything.

https://ow.ly/5VtG50X1ggE

Clinton Foundation